Several other research firms also recently issued reports on PFE. Sanford C. Bernstein reissued a buy rating and issued a $35.00 price target on shares of Pfizer in a research report on Monday, April 24th. Jefferies Group LLC reissued a hold rating and issued a $35.00 price target (up previously from $34.00) on shares of Pfizer in a research report on Friday, July 14th. BidaskClub downgraded shares of Pfizer from a sell rating to a strong sell rating in a research report on Thursday, July 13th. Zacks Investment Research raised shares of Pfizer from a sell rating to a hold rating in a report on Friday, July 14th. Finally, Morgan Stanley reaffirmed a neutral rating and set a $35.00 price objective (down from $38.00) on shares of Pfizer in a report on Monday, June 12th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the stock. Pfizer has a consensus rating of Hold and an average target price of $37.77.
Pfizer (NYSE:PFE) traded down 0.51% on Tuesday, hitting $33.25. 12,928,473 shares of the stock traded hands. The company has a market cap of $198.43 billion, a price-to-earnings ratio of 24.32 and a beta of 1.00. Pfizer has a 1-year low of $29.83 and a 1-year high of $35.38. The stock has a 50-day moving average price of $33.40 and a 200 day moving average price of $33.31.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The company had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the business posted $0.64 EPS. Pfizer’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, analysts anticipate that Pfizer will post $2.56 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This article was posted by BNB Daily and is owned by of BNB Daily. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/13/pfizer-inc-nysepfe-given-a-39-00-price-target-at-berenberg-bank-updated.html.
The business also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, August 4th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.85%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s dividend payout ratio is presently 94.12%.
In related news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the transaction, the insider now owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of PFE. Guardian Capital Advisors LP raised its stake in shares of Pfizer by 9.5% in the fourth quarter. Guardian Capital Advisors LP now owns 136,655 shares of the biopharmaceutical company’s stock valued at $4,593,000 after buying an additional 11,886 shares in the last quarter. Zurich Insurance Group Ltd FI raised its stake in shares of Pfizer by 8.8% in the fourth quarter. Zurich Insurance Group Ltd FI now owns 919,985 shares of the biopharmaceutical company’s stock valued at $29,881,000 after buying an additional 74,582 shares in the last quarter. Davy Asset Management Ltd raised its stake in shares of Pfizer by 0.5% in the fourth quarter. Davy Asset Management Ltd now owns 429,635 shares of the biopharmaceutical company’s stock valued at $16,017,000 after buying an additional 2,124 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Pfizer by 12.2% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,031,498 shares of the biopharmaceutical company’s stock valued at $33,500,000 after buying an additional 112,465 shares in the last quarter. Finally, Tyers Asset Management LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at about $4,228,000. Institutional investors own 70.10% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.